The ADC, SGN-75, conjugated with the microtubule inhibitor auristatin, has also demonstrated potent activity in preclinical tumor models [26–29] and was the subject of a clinical trial in CD70-positive NHL and metastatic RCC patients (see clinical trial number NCT01015911). Here, CD70 is linked to non-Hodgkin lymphoma.